Identification and Validation of a Potential Prognostic 7-lncRNA Signature for Predicting Survival in Patients with Multiple Myeloma

Figure 3

The robustness of the 7-lncRNA signature. (a) Risk score, survival time, survival status, and expression of 7 lncRNA in the internal validation set GSE4581. (b) ROC curve and AUC of a 7-lncRNA signature in the internal validation set GSE4581. (c) KM survival curve distribution of a 7-lncRNA signature in the internal validation set GSE4581. (d) Risk score, survival time, survival status, and expression of 7 lncRNAs in the entire dataset GSE4581. (e) ROC curve and AUC of a 7-lncRNA signature in the entire dataset GSE4581. (f) KM survival curve distribution of a 7-lncRNA signature in the entire dataset GSE4581. (g) Risk score, survival time, survival status, and expression of 7-lncRNA in the external validation set GSE57317. (h) ROC curve and AUC of a 7-lncRNA signature in the external validation set GSE57317. (i) KM survival curve distribution of a 7-lncRNA signature in the external validation set GSE57317.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)